Dr. Michael Reihart, with Penn State Health, also explained who's most at risk for severe illness and how effective this year's vaccine is.

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Here are four more respiratory illness updates: Nearly 1.7% of all deaths nationwide were attributed to flu, compared to approximately 1.5% from COVID-19. Influenza test positivity rose to 31.6%, ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Dr. Smith is the president of the Tennessee Chapter of the American Academy of Pediatrics.

The U.S. has seen earlier and more intense surges of the flu and RSV this year than is typical, pediatrician Dr. Ryan Fulton ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Babies under 8 months old are eligible to get an RSV vaccine, and women who are pregnant can also get it to protect kids before they're born. The vaccine is available now through March. If you have ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...

RSV infection that is managed via primary care in children under 5 years of age leads to a substantial burden for families, primary care resources, and society.

The flu just won’t quit this year. The virus seemed to peak after the December holidays in Massachusetts, headed back down, ...

RSV season is in full swing, according to doctors at Children’s Hospital Colorado. Denver7 spoke with a local family that is all too familiar with the infection.